World Parkinson Congress Blog

A Cup of Coffee

A Cup of Coffee

by Suketu M. Khandhar, MD

Living with Parkinson'sSuketu M. Khandhar, MDNovember 26, 2018Parkinson, three

What WPC means to me - the patient’s view

What WPC means to me - the patient’s view

By Richard Windle, M.Sc

AdvocacyRichard WindleNovember 19, 2018Advocacy, World Parkinson Congress, three

The Difference Between Parkinson's Disease and Lewy Body Dementia

The Difference Between Parkinson's Disease and Lewy Body Dementia

by Simon JG Lewis

Clinical ScienceSimon LewisNovember 13, 2018three

Sing to the Choir

Sing to the Choir

by Suzette Shahmoon, PhD Candidate

Comprehensive LivingSuzette Shahmoon, PhD CandidateOctober 23, 2018wellness, self care, positive psychology, three

Patient-Centered Care: A Paradigm Whose Time Has Come

Patient-Centered Care: A Paradigm Whose Time Has Come

by Laurie K Mischley ND, PhD, MPH

Clinical ScienceLaurie K. Mischley ND, PhD, MPHOctober 8, 2018three

Bridging the Gap: Insights & Strategies from Doctors who are Patients

Bridging the Gap: Insights & Strategies from Doctors who are Patients

By Pamela Quinn

AdvocacyPamela QuinnOctober 1, 2018three, World Parkinson Congress

Alpha-Synuclein Biomarker Development for PD Research

Alpha-Synuclein Biomarker Development for PD Research

by Leonidas Stefanis, MD, PhD

Clinical ScienceLeonidas Stefanis MD, PhDSeptember 21, 2018three, Alpha-Synuclein, parkinson's disease, Research

Teamwork and Collaboration - World Parkinson Congress' Impact and Influence

Teamwork and Collaboration - World Parkinson Congress' Impact and Influence

by Helen Matthews

AdvocacyHelen MatthewsSeptember 13, 2018three, Tom Isaacs, Cure Parkinson's Trust

Creating Community

Creating Community

by Sarah Jones, MPA, MS

AdvocacySarah Jones MPA, MSAugust 30, 2018three, community building

Procrastinator or Planner? At the Crossroads

Procrastinator or Planner? At the Crossroads

by Lissa Kapust, LICSW

Comprehensive LivingLissa Kapust, LICSWAugust 20, 2018Planning, Care Partners, Parkinson's, three

Why I Am Excited and Optimistic About the Prospects of Finding Neuroprotective Therapies in Parkinson's Disease

Why I Am Excited and Optimistic About the Prospects of Finding Neuroprotective Therapies in Parkinson's Disease

by Tanya Simuni, MD

Clinical ScienceTanya Simuni, MDAugust 15, 2018neuroprotection, Disease Modification, parkinson's disease, three

Etiquette in Clinical Research: Some Do's and Don'ts When You Sign Up

Etiquette in Clinical Research: Some Do's and Don'ts When You Sign Up

By Simon Stott, PhD

Clinical ScienceSimon Stott, PhDAugust 13, 2018clinical, research, rules, study, three

Parkinson's Research - Are We Standing Still or Making Progress?

Parkinson's Research - Are We Standing Still or Making Progress?

By Lisa M. Shulman, MD

Clinical ScienceLisa M. Shulman, MDAugust 6, 2018three, Research, Parkinson's Disease

Why Does It Take So Long?

Why Does It Take So Long?

By Tom Foltynie, PhD, MD, MRCP

Clinical ScienceTom Foltynie PhD, MD, MRCPJuly 30, 2018three

Anyone Can Improve Their Balance

Anyone Can Improve Their Balance

by Fay B. Horak PhD, PT

Comprehensive LivingFay B. Horak PhD, PTJuly 24, 2018three, balance, fall prevention, tai chi, boxing, dance

Bacteria and Parkinson's Disease

Bacteria and Parkinson's Disease

by Kathleen M. Shannon, MD

Basic ScienceKathleen M. Shannon, MDJuly 16, 2018three, gut microbiome, bacteria

Hope and the Top of the Pyramid

Hope and the Top of the Pyramid

by Suzette Shahmoon, PhD Candidate

Comprehensive Living, Living with Parkinson'sSuzette Shahmoon, PhD CandidateJuly 9, 2018three, DBS, Deep Brain Stimulation, Hope

Finding the Keys to Living Well with Parkinson's

Finding the Keys to Living Well with Parkinson's

by Jane Busch, DDS

Living with Parkinson'sJane Busch, DDSJuly 3, 2018three, Living Well, YOPD, Young onset

Fear is a Four-Letter Word

Fear is a Four-Letter Word

by Allison Toepperwein

Living with Parkinson'sKathleen JordanJune 25, 2018three, Gratitude

Why Have We Failed In Our Attempts To Develop A Neuroprotective Therapy For Parkinson's? How Can We Improve This Situation?

Why Have We Failed In Our Attempts To Develop A Neuroprotective Therapy For Parkinson's? How Can We Improve This Situation?

by A. Jon Stoessl CM, MD FRCPC

Clinical ScienceA. Jon Stoessl CM, MD FRCPCJune 18, 2018three, neuroprotection, Alpha-Synuclein, GBA